Scarica l'app Stockscreener
216.12
3.04%
6.38
Dopo l'orario di chiusura:
216.12
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Biogen Inc Borsa (BIIB) Ultime notizie
Biogen Says Research, Milestone Charges to Reduce Earnings in Q2, Q3 - marketscreener.com
Biogen (BIIB) Projects Significant Expenses for 2026 - GuruFocus
Biogen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Biogen (NASDAQ: BIIB) projects large 2026 R&D milestone charges hitting EPS - Stock Titan
The Spinraza therapyBiogen Inc. leans on long-term SMA demand - AD HOC NEWS
Amgen or Biogen: Which Biotech Stock Appears Better Poised? - TradingView
BIIBBiogen Inc Latest SEC Filings - Finviz
Biogen reports steady outlook, analysts weigh Alzheimer’s and neurology pipeline - AD HOC NEWS
Biogen Inc.(NasdaqGS: BIIB) dropped from Russell 1000 Value-Defensive Index - marketscreener.com
Biogen Inc.(NasdaqGS: BIIB) dropped from Russell 1000 Defensive Index - marketscreener.com
Biogen: Key Takeaways From Needham’s Meeting With Top Management - Benzinga
Biogen (BIIB) Moves 7.0% Higher: Will This Strength Last? - Yahoo Finance
Block & Leviton LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Biogen, Inc. – BIIB - GlobeNewswire Inc.
Biogen to present Alzheimer’s drug data at upcoming conference - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen - Biogen
Biogen to Highlight Breadth of Alzheimer’s Disease - GlobeNewswire
BIIB Maintained by Needham -- Price Target Raised to $256 - GuruFocus
The Vumerity from Biogen Inc.oral MS therapy with a quieter side-effect profile - AD HOC NEWS
Biogen Inc. stock outperforms competitors on strong trading day - MSN
Biogen (BIIB) Is Up 9.9% After US$1 Billion RayThera Deal And Salanersen WinHas The Bull Case Changed? - simplywall.st
Biogen shares at a four month high, analysts still watch BIIB - Ad-hoc-news.de
Biogen (BIIB) Research Report - StockStory
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Biogen clears a fresh 52-week high, shares react to RayThera deal and FDA tag - AD HOC NEWS
Enterprise value to revenue forward of Biogen Inc. – MUN:IDP - TradingView
Biogen (BIIB) Is Betting Its Next Phase Of Growth On Four New Drugs - simplywall.st
Biogen Inc (BIIB) Shares Surge 7.0% -- What GF Score of 74 Tells Investors - GuruFocus
Why Biogen (BIIB) Stock Is Up Today - Yahoo Finance
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout - Reuters
Biogen Jumps 6.1% Amid Sector-Wide Rally - AlphaStreet
Can Biogen's New Drugs Revive Growth Amid Legacy Sales Slump? - Yahoo Finance
Biogen reaches fresh 52-week high, shares extend strong S&P 500 run - Ad-hoc-news.de
Enterprise value to EBIT forward of Biogen Inc. – NASDAQ:BIIB - TradingView
Biogen Inc. stock underperforms Thursday when compared to competitors - MSN
Biogen Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Enterprise value to EBIT forward of Biogen Inc. – HAM:IDP - TradingView
Biogen marks a fresh 52-week high, shares extend NASDAQ biotech rally - Ad-hoc-news.de
Biogen stock reaches 52-week high at 206.21 USD By Investing.com - Investing.com South Africa
Biogen stock reaches 52-week high at 206.21 USD - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc.BIIB - PR Newswire
Price to sales forward of Biogen Inc. – NASDAQ:BIIB - TradingView
Biogen (BIIB) Could Be 9% Undervalued As Pipeline Hopes Shape The Valuation - simplywall.st
Enterprise value to EBITDA forward of Biogen Inc. – NASDAQ:BIIB - TradingView
Price to book forward of Biogen Inc. – TURQUOISE:BIIBN - TradingView
Enterprise value to revenue forward of Biogen Inc. – NASDAQ:BIIB - TradingView
Price to earnings forward of Biogen Inc. – NASDAQ:BIIB - TradingView
Biogen Expands Spinraza Patent Fight With Cipla, Somerset Suits - Bloomberg Law News
Biogen updates Alzheimer’s pipeline plans, shares on Nasdaq in focus - Ad-hoc-news.de
Law firm investigates Biogen for possible securities fraud after study misses key endpoint, stock drops 6.4%. - Pluang
Biogen to Acquire RayThera for Up to $1 Billion - Global Legal Chronicle
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Omada Health, Inc. (OMDA) - The Globe and Mail
WilmerHale Advises Biogen in Acquisition of RayThera - WilmerHale
Cantor Fitzgerald maintains Biogen stock rating on BIIB080 outlook - Investing.com
Biogen to acquire RayThera for USD 1B - Medical Buyer
Biogen Inc. (BIIB) Investor Outlook: Evaluating the Potential 12% Upside with Strong Buy Ratings - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Is Investigating Biogen Inc. (BIIB) And Encourages Shareholders to Connect - ACCESS Newswire
1.84%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):